252 related articles for article (PubMed ID: 30962346)
1. Novel MenA Inhibitors Are Bactericidal against
Berube BJ; Russell D; Castro L; Choi SR; Narayanasamy P; Parish T
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962346
[No Abstract] [Full Text] [Related]
2. Combinations of Respiratory Chain Inhibitors Have Enhanced Bactericidal Activity against Mycobacterium tuberculosis.
Berube BJ; Parish T
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061760
[TBL] [Abstract][Full Text] [Related]
3. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.
Ruth MM; Sangen JJN; Remmers K; Pennings LJ; Svensson E; Aarnoutse RE; Zweijpfenning SMH; Hoefsloot W; Kuipers S; Magis-Escurra C; Wertheim HFL; van Ingen J
J Antimicrob Chemother; 2019 Apr; 74(4):935-943. PubMed ID: 30649327
[TBL] [Abstract][Full Text] [Related]
4. Isoniazid Bactericidal Activity Involves Electron Transport Chain Perturbation.
Zeng S; Soetaert K; Ravon F; Vandeput M; Bald D; Kauffmann JM; Mathys V; Wattiez R; Fontaine V
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642937
[TBL] [Abstract][Full Text] [Related]
5. A Novel Small-Molecule Inhibitor of the
Sukheja P; Kumar P; Mittal N; Li SG; Singleton E; Russo R; Perryman AL; Shrestha R; Awasthi D; Husain S; Soteropoulos P; Brukh R; Connell N; Freundlich JS; Alland D
mBio; 2017 Feb; 8(1):. PubMed ID: 28196957
[TBL] [Abstract][Full Text] [Related]
6. Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis.
Foo CS; Lupien A; Kienle M; Vocat A; Benjak A; Sommer R; Lamprecht DA; Steyn AJC; Pethe K; Piton J; Altmann KH; Cole ST
mBio; 2018 Oct; 9(5):. PubMed ID: 30301850
[TBL] [Abstract][Full Text] [Related]
7. Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis.
Lechartier B; Cole ST
Antimicrob Agents Chemother; 2015 Aug; 59(8):4457-63. PubMed ID: 25987624
[TBL] [Abstract][Full Text] [Related]
8. Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis.
Debnath J; Siricilla S; Wan B; Crick DC; Lenaerts AJ; Franzblau SG; Kurosu M
J Med Chem; 2012 Apr; 55(8):3739-55. PubMed ID: 22449052
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds
Li W; Sanchez-Hidalgo A; Jones V; de Moura VC; North EJ; Jackson M
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115355
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan.
Ghodousi A; Rizvi AH; Baloch AQ; Ghafoor A; Khanzada FM; Qadir M; Borroni E; Trovato A; Tahseen S; Cirillo DM
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262765
[TBL] [Abstract][Full Text] [Related]
11. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
[TBL] [Abstract][Full Text] [Related]
12. Identification of 4-Amino-Thieno[2,3-
Harrison GA; Mayer Bridwell AE; Singh M; Jayaraman K; Weiss LA; Kinsella RL; Aneke JS; Flentie K; Schene ME; Gaggioli M; Solomon SD; Wildman SA; Meyers MJ; Stallings CL
mSphere; 2019 Sep; 4(5):. PubMed ID: 31511370
[TBL] [Abstract][Full Text] [Related]
13. Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis.
Gold B; Roberts J; Ling Y; Quezada LL; Glasheen J; Ballinger E; Somersan-Karakaya S; Warrier T; Warren JD; Nathan C
Antimicrob Agents Chemother; 2015 Oct; 59(10):6521-38. PubMed ID: 26239979
[TBL] [Abstract][Full Text] [Related]
14. Clofazimine Exposure
Ismail N; Peters RPH; Ismail NA; Omar SV
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642938
[TBL] [Abstract][Full Text] [Related]
15. Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis.
Chen C; Gardete S; Jansen RS; Shetty A; Dick T; Rhee KY; Dartois V
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463541
[No Abstract] [Full Text] [Related]
16. Exploiting the synthetic lethality between terminal respiratory oxidases to kill
Kalia NP; Hasenoehrl EJ; Ab Rahman NB; Koh VH; Ang MLT; Sajorda DR; Hards K; Grüber G; Alonso S; Cook GM; Berney M; Pethe K
Proc Natl Acad Sci U S A; 2017 Jul; 114(28):7426-7431. PubMed ID: 28652330
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
Kim S; Louie A; Drusano GL; Almoslem M; Kim S; Myrick J; Nole J; Duncanson B; Peloquin CA; Scanga CA; Yamada W; Neely M; Schmidt S
Int J Antimicrob Agents; 2022 Feb; 59(2):106509. PubMed ID: 34958863
[TBL] [Abstract][Full Text] [Related]
18. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.
Hartkoorn RC; Uplekar S; Cole ST
Antimicrob Agents Chemother; 2014 May; 58(5):2979-81. PubMed ID: 24590481
[TBL] [Abstract][Full Text] [Related]
19. InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis.
Flint L; Korkegian A; Parish T
PLoS One; 2020; 15(11):e0239354. PubMed ID: 33201882
[TBL] [Abstract][Full Text] [Related]
20. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N
Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
